Dr. Reddy's, Hetero obtain royalty-free licensing for HIV treatment Lenacapavir in India and 120 low-income countries.

Dr. Reddy's Laboratories and Hetero have secured royalty-free licensing agreements with Gilead Sciences to manufacture and distribute Lenacapavir, an innovative HIV treatment, in India and 120 low- and lower-middle-income countries. This partnership aims to enhance access to this USFDA-approved drug, which targets multi-drug-resistant HIV, and support HIV prevention efforts. The goal is to improve treatment options for underserved populations facing high disease burdens.

October 02, 2024
47 Articles